Science & Technology
CDG is developing and reporting on its pipeline of cell penetrating peptides (CPPs) in the areas of metastatic, p53 positive solid tumors, neoangiogenesis, carriers for contrast and functional imaging agents, and inhibition of pathogen entry into host cells. One particular aspect we have successfully explored is the ability of these peptides to cross the blood brain barrier, preferentially enter and be retained by cancer cells relative to normal brain tissue. This opens a new and unique research avenue in the treatment of primary CNS tumors and tumors metastatic to the brain. The pool of structures currently available to choose from, as well as a rich pipeline of peptide drug prototypes and analogs, all available inexpensively through chemical synthesis, provides a significant opportunity for development.